• Recruiting

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma

FT576 in Subjects With Multiple Myeloma

FT576

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.


Sponsor

Fate Therapeutics

 

ClinicalTrials.gov Identifier: NCT05182073


Official Title: A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma


First Posted: January 10, 2022


Click here for details on ClinicalTrials.gov

 

FT 576


iPSC-derived Anti-BCMA CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT576 (Code C186430)

CD16/IL-15RF-expressing CD38-eliminated Anti-BCMA CAR-iNK Cells FT576

FT 576

FT-576

FT576

iPSC-derived Anti-BCMA CAR-CD16-IL-15RF-expressing CD38-eliminated NKs FT576

iPSC-derived Anti-BCMA CAR/CD16/IL-15RF-expressing CD38-eliminated Natural Killer Cells FT576

iPSC-derived Anti-BCMA CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT576

iPSC-derived CD16/IL-15RF-expressing CD38-eliminated Anti-BCMA CAR-NK Cells FT576

 

Drug: FT576 (Allogenic CAR NK cells with BCMA expression)

Drug: Cyclophosphamide

Drug: Fludarabine

Drug: Daratumumab

 

Locations

United States, Alabama

United States, Colorado

United States, Indiana

United States, Tennessee

United States, Wisconsin

Posts Archive